The latest data point for LLY's EV/Sales ratio in Q1'26 stands at 43.48, reflecting a moderate decline from the previous quarter's value of 52.60 in Q4'25 and indicating a potential stabilization at lower multiples amid market adjustments. Over the period from Q2'23 to Q1'26, the EV/Sales ratio exhibited an initial upward trend, peaking at 87.38 in Q1'24, driven by strong growth expectations, before entering a sustained decline to 43.48, with notable volatility including a sharp drop to 41.33 in Q2'25 followed by partial recoveries in subsequent quarters. This pattern suggests diminishing valuation premiums relative to sales, possibly due to competitive pressures or maturing growth in the pharmaceutical sector, with an overall average around 60 across the timeframe.